Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
Multiple system atrophy (MSA) is an adult-onset, rapidly progressive neurodegenerative disorder characterised by the aggregation of α-synuclein in oligodendroglial cytoplasmatic inclusions.1 ...
- Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders - The posters presented from Alterity’s bioMUSE study address the need for incorporating biomarkers as a ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ('Alterity” or 'the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Multiple System Atrophy is an unmet medical need as there are currently no FDA approved therapies to treat this life limiting, orphan designated disease. The Phase 2a study (ClinicalTrials.gov ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results